BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
December 11, 2017 at 17:31 PM EST
* MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL
